DLBCL: Clinical Data
L. Ceriani, Bellinzona (Switzerland), et al.
Authors Conclusion from the abstract: Baseline MTV is a powerful predictor of clinical outcomes in patients with DLBCL treated with R‐CHOP. High MTV values predict a worse response to treatment especially in patients with non‐GCB subtype. A prognostic model based on the combination of MTV and MH may allow the early identification of patients at high risk of disease progression following conventional treatment. The validation of these results in an independent retrospective cohort of patients treated with R‐CHOP21 is ongoing and full data will be presented.
J.R. Westin, Houston, TX (USA), et al.
Authors Conclusion from the abstract: The Smart Start trial demonstrates the chemotherapy‐free combination of rituximab 375 mg/m2, ibrutinib 560 mg, and lenalidomide 25mg is highly effective in patients with newly diagnosed non‐GCB DLBCL. Further studies are planned with other novel agents and with fewer cycles of chemotherapy consolidation for patients achieving a CR with RLI alone.
P. Lugtenburg, Rotterdam (Netherlands), et al.
Authors Conclusion from the abstract: Rituximab maintenance therapy provides no additional benefit for DLBCL patients in first CR after R‐CHOP.
T. Shree, Stanford, CA (USA), et al.
IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A LARGE POPULATION-BASED STUDY
Authors Conclusion from the abstract: These findings, from a large, population‐based cohort, show that immune‐related conditions in DLBCL survivors are wide‐ranging, and increased risk for these conditions is long‐lasting. These data highlight a need to understand the mechanisms of immune dysfunction and to define predictors of clinical risk among DLBCL survivors.